Fosun Pharma's HLX13 Phase I Clinical Trial Application for First-Line Treatment of Unresectable Hepatocellular Carcinoma (HCC) Patients Approved by the FDA.

Zhtng Cijng APP Xn, Fhng Hnln (02696.HK) gngb, jnr, gngs zzh ynf de Y p m dnkng shngw lis yo HLX13 (chngz kng CTLA-4 qun rn dn k nng tizhng y) (HLX13) yxin zhlio b k qich de gn xbi cncr (HCC) hunzh de 1 q lnghu shyn shnqng (IND) hu migu shpn yo fngun (FDA) pzhn. Gngs n y tiojin jbi hu y migu kizhn gi guj du zhngxn lnghu shyn.